16 September 2026 editorial review · Trial
LUMC Phase 1b: tolerogenic dendritic cells in recent-onset T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Current LUMC June 26 primary news confirms 10 planned participants and diagnosis within five years and first participant treatment; n=1 safety anecdote is not efficacy. Dynamic CTIS full record was not independently available in this pass.
Sources for this record: EUCT 2023-508558-25-01: Tolerogenic dendritic cell therapy in type 1 diabetes (registry); First patient treated in new phase of promising type 1 diabetes research (news).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.